SUZHOU, China, and ROCKVILLE, MD, December 13, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized, controlled, registrational Phase II study of the company’s novel drug candidate, olverembatinib (R&D code: HQP1351), in
Read More ›